EMA Recommends Extension of Therapeutic Indications for Ponatinib By Ogkologos - February 27, 2026 138 0 Facebook Twitter Google+ Pinterest WhatsApp Source RELATED ARTICLESMORE FROM AUTHOR EMA Recommends Granting a Marketing Authorisation for Generic Palbociclib Metastasis-Directed Therapy for Oligometastatic Solid Tumours in Histology-Specific Context ctDNA Testing After Neoadjuvant Chemotherapy and Radical Cystectomy Predicts Recurrence Risk in Patients with MIBC MOST POPULAR Although Not Improving DFS, Adjuvant Avelumab May Potentially Reduce the Risk... September 9, 2025 Could proton beam therapy improve throat cancer treatment? March 15, 2021 FDA Grants Accelerated Approval to Epcoritamab-bysp for Relapsed or Refractory Follicular... July 31, 2024 New on NCI’s Websites for June 2020 June 26, 2020 Load more HOT NEWS Long-Term Outcomes from the CheckMate 067 Study in Patients With Advanced... Ivosidenib with Chemotherapy New Option for Some People with AML Interpreted cancer awareness workshops: talking about cancer with South-Asian communities How I Navigated Being a Young Mom During Cancer: A Survivor’s...
